within Pharmacolibrary.Drugs.ATC.A;

model A07EC03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.03,
    Cl             = 0.000295,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0167,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0015,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A07EC03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Olsalazine is an anti-inflammatory drug used primarily in the treatment of inflammatory bowel disease, particularly ulcerative colitis. It is a prodrug that is converted in the colon to mesalazine (5-aminosalicylic acid), the active moiety. Olsalazine is approved for use in the maintenance of remission of ulcerative colitis.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers following oral administration.</p><h4>References</h4><ol><li><p>Campbell, DE, &amp; Berglindh, T (1988). Pharmacology of olsalazine. <i>Scandinavian journal of gastroenterology. Supplement</i> 148 7–12. DOI:<a href=&quot;https://doi.org/10.3109/00365528809101539&quot;>10.3109/00365528809101539</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3067340/&quot;>https://pubmed.ncbi.nlm.nih.gov/3067340</a></p></li><li><p>Ryde, EM, &amp; Ahnfelt, NO (1988). The pharmacokinetics of olsalazine sodium in healthy volunteers after a single i.v. dose and after oral doses with and without food. <i>European journal of clinical pharmacology</i> 34(5) 481–488. DOI:<a href=&quot;https://doi.org/10.1007/BF01046706&quot;>10.1007/BF01046706</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3203708/&quot;>https://pubmed.ncbi.nlm.nih.gov/3203708</a></p></li><li><p>Segars, LW, &amp; Gales, BJ (1992). Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease. <i>Clinical pharmacy</i> 11(6) 514–528. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1600685/&quot;>https://pubmed.ncbi.nlm.nih.gov/1600685</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A07EC03;
